我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。
相关临床试验
76
16 进行中
药物批准
0
批准总数
监管机构
监管机构数
成立时间
N/A
进行中（未招募）
14
18.4%
已完成
33
43.4%
尚未招募
2
2.6%
招募中
16
21.1%
终止
7
9.2%
撤回
4
5.3%
暂无批准数据
- CHOSA will release results from a blinded retrospective study predicting cisplatin efficacy in lung cancer patients from the SPLENDOUR trial by the end of Q2 2025, potentially revolutionizing treatment selection. - The company's Drug Response Predictor (DRP) for platinum drugs demonstrated significant clinical value in breast cancer, where a 50% difference in DRP score corresponded to a three-fold difference in carboplatin treatment benefit. - CHOSA's predictive technology could enhance the efficacy of platinum-based therapies across multiple cancer types and improve outcomes when combined with immunotherapy, addressing a critical need in the $60 billion PD-1/PD-L1 market.
